Stock PYFA PT PYRIDAM FARMA TBK
Add to a list
To use this feature you must be a member
Log inSign up

Financials PT Pyridam Farma Tbk

Equities

PYFA

ID1000075609

Pharmaceuticals

End-of-day quote INDONESIA S.E.
Other stock markets
 06:00:00 2024-06-04 pm EDT 		5-day change 1st Jan Change
113 IDR -4.24% Intraday chart for PT Pyridam Farma Tbk -14.39% -90.13%
May. 10 Foreign Investment Review Board Clears Probiotec Acquisition by Pyridam Farma MT
Mar. 15 PT Pyridam Farma Tbk Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 101,130 105,946 521,703 543,106 462,844 612,667
Enterprise Value (EV) 1 123,698 120,061 547,580 944,187 1,236,303 1,509,688
P/E ratio 12 x 11.3 x 23.6 x 99.1 x 1.68 x -7.19 x
Yield 2.12% - - - - -
Capitalization / Revenue 0.4 x 0.43 x 1.88 x 0.86 x 0.65 x 0.87 x
EV / Revenue 0.49 x 0.49 x 1.97 x 1.5 x 1.73 x 2.15 x
EV / EBITDA 5.94 x 5.54 x 14 x 15.1 x 20.3 x 28 x
EV / FCF -8.2 x 13.6 x -81.9 x -4.64 x -6.69 x -16.8 x
FCF Yield -12.2% 7.34% -1.22% -21.6% -14.9% -5.95%
Price to Book 0.85 x 0.85 x 3.31 x 3.25 x 1.05 x 1.72 x
Nbr of stocks (in thousands) 535,080 535,080 535,080 535,080 535,080 535,080
Reference price 2 189.0 198.0 975.0 1,015 865.0 1,145
Announcement Date 3/27/19 3/30/20 6/30/21 5/9/22 4/6/23 3/15/24
1IDR in Million2IDR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 250,446 247,115 277,398 630,530 715,425 702,068
EBITDA 1 20,838 21,653 39,154 62,664 60,935 53,948
EBIT 1 13,538 14,231 31,401 37,526 -4,412 1,758
Operating Margin 5.41% 5.76% 11.32% 5.95% -0.62% 0.25%
Earnings before Tax (EBT) 1 11,317 12,519 29,642 8,811 263,080 -83,248
Net income 1 8,447 9,343 22,104 5,479 275,472 -85,221
Net margin 3.37% 3.78% 7.97% 0.87% 38.5% -12.14%
EPS 2 15.79 17.46 41.31 10.24 514.8 -159.3
Free Cash Flow 1 -15,089 8,814 -6,684 -203,649 -184,823 -89,793
FCF margin -6.02% 3.57% -2.41% -32.3% -25.83% -12.79%
FCF Conversion (EBITDA) - 40.71% - - - -
FCF Conversion (Net income) - 94.34% - - - -
Dividend per Share 2 4.000 - - - - -
Announcement Date 3/27/19 3/30/20 6/30/21 5/9/22 4/6/23 3/15/24
1IDR in Million2IDR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 22,568 14,115 25,877 401,080 773,458 897,021
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 1.083 x 0.6519 x 0.6609 x 6.401 x 12.69 x 16.63 x
Free Cash Flow 1 -15,089 8,814 -6,684 -203,649 -184,823 -89,793
ROE (net income / shareholders' equity) 7.42% 7.67% 15.7% 3.37% 90.4% -21.3%
ROA (Net income/ Total Assets) 4.88% 4.71% 9.36% 4.53% -0.24% 0.07%
Assets 1 173,036 198,443 236,168 120,868 -116,232,916 -118,034,591
Book Value Per Share 2 222.0 233.0 295.0 312.0 826.0 667.0
Cash Flow per Share 2 3.650 9.900 18.00 89.20 255.0 168.0
Capex 1 20,444 3,235 7,695 218,735 37,315 13,364
Capex / Sales 8.16% 1.31% 2.77% 34.69% 5.22% 1.9%
Announcement Date 3/27/19 3/30/20 6/30/21 5/9/22 4/6/23 3/15/24
1IDR in Million2IDR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
PT PYRIDAM FARMA TBK Stock PT Pyridam Farma Tbk
-90.13% 81.63M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+42.69% 750B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+34.11% 606B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.87% 356B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.74% 326B
ABBVIE INC. Stock AbbVie Inc.
+6.76% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.08% 246B
ROCHE HOLDING AG Stock Roche Holding AG
-3.44% 213B
NOVARTIS AG Stock Novartis AG
+11.35% 213B
PFIZER, INC. Stock Pfizer, Inc.
+2.64% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. PYFA Stock
  4. Financials PT Pyridam Farma Tbk